Share
Products & Operating Company
Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®
Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®
Share

Raritan, NJ (October 5, 2011) – Today Scios Inc. announced an agreement with the United States Department of Justice to resolve allegations of misbranding of NATRECOR® (nesiritide), a prescription medication for patients with heart failure.

As part of this agreement, Scios Inc. entered a guilty plea to a single misdemeanor violation of the Food, Drug and Cosmetic Act, and agreed to pay an $85 million fine.

Scios acknowledges that NATRECOR® was misbranded and used in a way not approved by the U.S. Food and Drug Administration because its labeling lacked adequate directions for that use, but denies any wrongful intent in connection with this plea.

###

Contact:
Media:
Shaun Mickus                                                
Office: (908) 927-2416                                  
smickus@its.jnj.com

Bill Foster
Cell: (908) 392-6057
wfoster@its.jnj.com

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue